DMTTF - Cybin Delivers Highest Dose Of Psilocybin Analog In Phase 2 For Major Depression | Benzinga
Clinical-stage psychedelics biotech Cybin (NYSE: CYBN) has completed enrollment in its Phase 2 study of novel deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive Disorder (MDD.)
All participants in the sixth and final cohort have reportedly received at least one dose (placebo or 16mg of CYB003) with several second doses already administered; no serious adverse events were observed.
In the other five participant cohorts, CYB003 has also so far shown a favorable safety and tolerability profile at all doses (1mg, 3mg, 8mg, 10mg and 12mg.)
Dosing of this last cohort would round up in early Q4 this year, shortly followed by topline efficacy results which would be submitted to the FDA and inform the company’s next "pivotal” studies.
Cybin aims to scale its clinical program around CYB003, which is protected by a U.S. patent until 2041, to a multinational Phase 3 study in ...